Adia Nutrition, Inc. is engaged in the creation of probiotics. The company is headquartered in Winter Park, Florida. The company went IPO on 2004-03-23. The Company’s divisions include supplement division and medical division. The supplement division provides organic supplements. The medical division establishes clinics that specialize in stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Adia Med of Winter Park, LLC, its subsidiary, operates clinic to perform treatments, and Adia Labs, LLC, its subsidiary, procures and sells the products relating to these procedures. Adia Med is conducting a nationwide rollout of satellite locations offering Umbilical Cord Stem Cell (UCB-SC) and exosome treatments, like AdiaVita from Adia Labs LLC, with at least 100 million stem cells and three trillion exosomes per unit. These therapies address chronic inflammation, autoimmune disorders, and orthopedic issues. The firm has approximately 18% equity position in Cement Factory, LLC.
How did ADIA's recent EPS compare to expectations?
The most recent EPS for Adia Nutrition Inc is $, expectations of $.
How did Adia Nutrition Inc ADIA's revenue perform in the last quarter?
Adia Nutrition Inc revenue for the last quarter is $
What is the revenue estimate for Adia Nutrition Inc?
According to of Wall street analyst, the revenue estimate of Adia Nutrition Inc range from $ to $
What's the earning quality score for Adia Nutrition Inc?
Adia Nutrition Inc has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Adia Nutrition Inc report earnings?
Adia Nutrition Inc next earnings report is expected in
What are Adia Nutrition Inc's expected earnings?
Adia Nutrition Inc expected earnings is $, according to wall-street analysts.
Did Adia Nutrition Inc beat earnings expectations?
Adia Nutrition Inc recent earnings of $ expectations.